使用 IL-18 装甲 CAR-T 细胞免疫治疗 DLL3 阳性小细胞肺癌的挑战与考量
Challenges and considerations in the immunotherapy of DLL3-positive small-cell lung cancer using IL-18 armoured chimeric antigen receptor T-cells.
32.4分
★☆☆☆☆
ALL SOURCES
Challenges and considerations in the immunotherapy of DLL3-positive small-cell lung cancer using IL-18 armoured chimeric antigen receptor T-cells.
共 1 条
MEMBER ACCOUNT
登录成功会直接打开下一页。